Home › Markets › Health Care › GH

Guardant Health Inc. (GH)

GH trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$162.09
-0.43% on the day
Market cap
$21.8B
Large cap
Revenue · 2025
$982.0M
+32.9% on 2024
Net income · 2025
-$416.3M
-42.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerGH on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryUnited States
IPO year2018
SEC CIK0001576280
SEC industry codeServices-Medical Laboratories
Incorporated inDE

Financials · 2025

LineValue
Revenue$982.0M
Net income-$416.3M
Operating income-$437.2M
Net margin-42.4%
Operating margin-44.5%
Revenue growth+32.9%
Cash$378.2M
Total assets$2.0B
P/E (computed)Net income was not positive
P/S (computed)22.1×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-07-30
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-07-30
Latest current report8-K2026-07-30
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.4%
1 month-7.4%
3 months+4.9%
Year to date+59.2%
1 year+163.5%
From 52-week high-13.1%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
LHLabcorp Holdings Inc.$313.64-0.60%$25.4B
DGXQuest Diagnostics Incorporated$230.46-0.93%$25.4B
CNCCentene Corporation$68.86+2.75%$34.0B
ILMNIllumina Inc.$271.18-1.99%$40.9B
MOHMolina Healthcare Inc$209.50+2.52%$10.9B
OSCROscar Health Inc.$33.79-0.65%$10.4B
HSICHenry Schein Inc.$85.03+0.95%$9.5B
HUMHumana Inc.$420.38-3.03%$50.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier